King's College London

Funding Information: Tahseen A. Chowdhury—None; Mona Wahba—None; Ritwika Mallik—None; Javeria Peracha—None; Dipesh Patel—has received honoraria for advisory work and/or lecture fees from AstraZeneca, Boehinger Ingelheim Eli Lilly, MSD and Napp Pharmaceuticals, Novo Nordisk and Sanofi; Parijat De—has received speaker honoraria from Novo Nordisk, Lilly, Sanofi, Napp, Boehringer‐Ingelheim, Astra and Pfizer; Damian Fogarty—declares speaker honoraria from Vifor, Napp and Pharmacosmos; Andrew Frankel—declares receipt of research grants, preparation of educational materials and attendance at drug advisory boards for Astra‐Zeneca, Boehringer Ingelheim/Lilly Alliance, Merck‐Sharpe and Dohme, Napp Pharmaceuticals Ltd and Novo Nordisk; Janaka Karralliedde—has received honoraria for delivering educational meetings and/or attending advisory boards Boehringer Ingelheim, Astra Zeneca, Sanofi, Janssen and Novo Nordisk. Research grants from: Astra Zeneca and Sanofi; Patrick B. Mark—reports speaker honoraria from Vifor, Astrazeneca, Janssen, Napp and Novartis; research grants from Boehringer Ingelheim and non‐financial support from Pharmacosmos; Rosa M Montero—None; Ana Pokrajac—non‐promotional speaker fees, advisory boards and conference attendance by NAPP and NovoNordisk and Ellie Lily‐BI Alliance; Sagen Zac‐Varghese—None; Steve C. Bain—reports honoraria, teaching and research sponsorship/grants from AstraZeneca, Boehringer Ingelheim, Eli Lilly & Co, GlaxoSmithKline, Merck Sharp & Dohme, Novo Nordisk, Roche, Sanofi‐Aventis, funding for development of educational programs from Cardiff University & Medscape. He owns a share of Glycosmedia and has provided expert advice to the All‐Wales Medicines Strategy Group and National Institute for Health and Care Excellence (NICE) UK; Indranil Dasgupta—None; Debasish Banerjee—None; Peter Winocour—has received honoraria for delivering educational meetings and/or attending advisory boards for Astra Zeneca, Boehringer Ingelheim, Eli Lilly, MSD, Napp, Sanofi, Novo and Vifor Pharmaceuticals; Adnan Sharif—reports advisory boards for Boehringer Ingelheim, Eli Lilly, Sandoz, Astellas, Atara Biotherapeutics, Novartis, honoraria and grant funding from Chesi, Napp Pharamceuticals, Eli Lilly and travel reimbursement from Sandoz, Novartis. Publisher Copyright: © 2021 Diabetes UK Copyright: Copyright 2021 Elsevier B.V., All rights reserved.